M Korc

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells
    M Kornmann
    Department of Medicine, University of California, Irvine 92697, USA
    Int J Pancreatol 29:85-92. 2001
  2. ncbi Diabetes mellitus in the era of proteomics
    Murray Korc
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697, USA
    Mol Cell Proteomics 2:399-404. 2003
  3. pmc Pathways for aberrant angiogenesis in pancreatic cancer
    M Korc
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Irvine, California 92697, USA
    Mol Cancer 2:8. 2003
  4. ncbi Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4
    M Kornmann
    Department of Medicine, University of California, Irvine 92697, USA
    Anticancer Res 19:125-31. 1999
  5. ncbi Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo
    J Luo
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of Irvine, Irvine, CA, USA
    Int J Cancer 92:361-9. 2001
  6. ncbi Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
    J Itakura
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of California, Irvine, CA, USA
    Int J Cancer 85:27-34. 2000
  7. ncbi Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer
    J Kleeff
    Department of Medicine, University of California, Irvine 92697, USA
    Int J Cancer 81:650-7. 1999
  8. ncbi Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells
    K Matsuda
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697, USA
    Cancer Res 61:5562-9. 2001
  9. ncbi Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo
    J Kleeff
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of California, Irvine, California, USA
    Gastroenterology 116:1202-16. 1999
  10. ncbi Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer
    J Kleeff
    Department of Medicine, University of California, Irvine 92697, USA
    Biochem Biophys Res Commun 255:268-73. 1999

Collaborators

Detail Information

Publications72

  1. ncbi Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells
    M Kornmann
    Department of Medicine, University of California, Irvine 92697, USA
    Int J Pancreatol 29:85-92. 2001
    ..FGF-5 is a secreted FGF that is believed to preferentially act via the IIIc splice variant of FGFR-1. Human pancreatic ductal carcinoma cells express FGF-5 and FGFR-1IIIc, implying a potential for autocrine growth modulation...
  2. ncbi Diabetes mellitus in the era of proteomics
    Murray Korc
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697, USA
    Mol Cell Proteomics 2:399-404. 2003
  3. pmc Pathways for aberrant angiogenesis in pancreatic cancer
    M Korc
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Irvine, California 92697, USA
    Mol Cancer 2:8. 2003
    ....
  4. ncbi Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4
    M Kornmann
    Department of Medicine, University of California, Irvine 92697, USA
    Anticancer Res 19:125-31. 1999
    ....
  5. ncbi Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo
    J Luo
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of Irvine, Irvine, CA, USA
    Int J Cancer 92:361-9. 2001
    ..These results support the hypothesis that VEGF promotes pancreatic cancer growth in vivo and suggest that anti-VEGF therapy may be useful in the treatment of this disease...
  6. ncbi Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
    J Itakura
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of California, Irvine, CA, USA
    Int J Cancer 85:27-34. 2000
    ..These data indicate that human pancreatic cancers have the capacity to over-express VEGF and its receptors and suggest that in some instances VEGF may directly promote pancreatic cancer growth via the MAPK pathway...
  7. ncbi Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer
    J Kleeff
    Department of Medicine, University of California, Irvine 92697, USA
    Int J Cancer 81:650-7. 1999
    ..Together, our findings suggest that Mip-3alpha has the potential to act via autocrine and paracrine mechanisms to contribute to the pathobiology of human pancreatic cancer...
  8. ncbi Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells
    K Matsuda
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697, USA
    Cancer Res 61:5562-9. 2001
    ....
  9. ncbi Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo
    J Kleeff
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of California, Irvine, California, USA
    Gastroenterology 116:1202-16. 1999
    ..We characterized the expression of BMP-2 and its receptors in human pancreatic tissues and pancreatic cancer cell lines and examined the effects of BMP-2 on mitogenesis...
  10. ncbi Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer
    J Kleeff
    Department of Medicine, University of California, Irvine 92697, USA
    Biochem Biophys Res Commun 255:268-73. 1999
    ..Thus, enhanced expression of the TGF-beta signaling inhibitor Smad6 in pancreatic cancer may present a novel mechanism of TGF-beta resistance, which might have the potential to enhance the transformed phenotype of human cancer cells...
  11. ncbi Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer
    J Kleeff
    Department of Medicine, University of California, Irvine 92697, USA
    Dig Dis Sci 44:1793-802. 1999
    ..It is suggested that pancreatic cancer cells have the capacity to up-regulate Smad2 expression, which may lead to excessive activation of specific components of the TGF-beta-signaling pathway...
  12. ncbi Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions
    M Kornmann
    Department of Medicine, Biological Chemistry and Pharmacology, University of California, Irvine 92697, USA
    Oncogene 15:1417-24. 1997
    ..These observations suggest that FGF-5 may participate in autocrine and paracrine pathways promoting pancreatic cancer cell growth in vivo...
  13. pmc The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer
    J Kleeff
    Departments of Medicine, Biological Chemistry, and Pharmacology, University of California, 92697, USA
    J Clin Invest 102:1662-73. 1998
    ....
  14. pmc Overexpression of activin A in stage IV colorectal cancer
    S Wildi
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Irvine, California, USA
    Gut 49:409-17. 2001
    ..CONCLUSIONS: Our findings indicate that activin A is overexpressed in human colorectal tumours, especially in stage IV disease, raising the possibility that activin A may have a role in advanced colorectal cancer...
  15. ncbi Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis
    H Friess
    Department of Medicine, University of California, Irvine 92717
    Int J Cancer 56:668-74. 1994
    ..These findings indicate that cripto expression may contribute to disease progression in pancreatic cancer, and implicate cripto in the histopathological alterations that occur in the pancreas both in cancer and in CP...
  16. pmc Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum
    M Kornmann
    Department of Medicine, University of California, Irvine, California 92697, USA
    J Clin Invest 101:344-52. 1998
    ..These findings indicate that cyclin D1 overexpression contributes to abnormal growth and tumorigenicity in human pancreatic cancer and to the resistance of pancreatic cancer to chemotherapeutic agents...
  17. ncbi Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation
    M A Rowland-Goldsmith
    Department of Medicine, University of California, Irvine, 92697, USA
    Clin Cancer Res 7:2931-40. 2001
    ....
  18. ncbi Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer
    M S Kobrin
    Department of Medicine, University of California, Irvine 92717
    Biochem Biophys Res Commun 202:1705-9. 1994
    ..These findings suggest that HB-EGF may participate in aberrant autocrine and paracrine activation of the EGF receptor, thereby contributing to pancreatic cancer cell growth...
  19. ncbi Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer
    M Wagner
    Department of Medicine, University of California, Irvine 92697, USA
    Pancreas 19:370-6. 1999
    ..It is suggested that TbetaRII overexpression may be a marker that correlates with disease progression in pancreatic ductal adenocarcinoma...
  20. ncbi Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer
    J Kleeff
    Department of Medicine, University of California, Irvine 92697, USA
    Int J Cancer 77:860-8. 1998
    ..Both the ligand and its receptors were often co-expressed in these cells. Together, our findings suggest that activin A may participate in autocrine activation of pancreatic cancer cells in vivo...
  21. ncbi Altered expression of insulin-like growth factor II receptor in human pancreatic cancer
    T Ishiwata
    Division of Endocrinology, Metabolism and Diabetes, University of California, Irvine 92697, USA
    Pancreas 15:367-73. 1997
    ....
  22. ncbi Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes
    M Kornmann
    Department of Medicine, University of California, Irvine 92697, USA
    Cancer Res 59:3505-11. 1999
    ....
  23. ncbi A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2
    M E Lopez
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697, USA
    J Biol Chem 275:15933-9. 2000
    ..These findings indicate that FGFR-1L binds FGF-1 and FGF-2 with high affinity and is capable of mitogenic signaling, but may activate MAPK to occur via non-classical signaling intermediates...
  24. ncbi Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma
    M Naef
    Department of Medicine, University of California, Irvine 92697, USA
    Int J Cancer 71:131-7. 1997
    ....
  25. ncbi TGF-beta-1 up-regulates cyclin D1 expression in COLO-357 cells, whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor
    M Kornmann
    Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry and Pharmacology, University of California, Irvine, CA, USA
    Int J Cancer 83:247-54. 1999
    ..Our findings suggest that in some cell types cyclin D1 expression may be important for TGF-beta1-mediated signaling and that cyclin D1 may be involved in the transcriptional regulation of TbetaRI...
  26. pmc The role of fibroblast growth factors in tumor growth
    M Korc
    Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Curr Cancer Drug Targets 9:639-51. 2009
    ....
  27. pmc In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain
    J Fallon
    Departments of Anatomy and Neurobiology, Medicine, and Pharmacology, University of California, Irvine, CA 92697 1275, USA
    Proc Natl Acad Sci U S A 97:14686-91. 2000
    ..This finding has significant implications with respect to the development of treatments for both acute neural trauma and neurodegenerative diseases...
  28. pmc AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia
    A M Norris
    Department of Medicine, Dartmouth Medical School, Hanover, NH, USA
    Oncogene 32:3867-76. 2013
    ....
  29. pmc A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis
    C A Whipple
    Department of Medicine, Dartmouth Medical School, Hanover, NH, USA
    Oncogene 31:2535-44. 2012
    ....
  30. ncbi Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer
    M Ebert
    Department of Medicine, University of California, Irvine 92717, USA
    Int J Cancer 62:529-35. 1995
    ..By immunohistochemistry, PDGF and both PDGF receptors were present in the cancer cells, and PDGFR beta was abundant in fibroblasts and endothelial cells within the connective tissue...
  31. pmc Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
    J M Pipas
    Section Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Ann Oncol 23:2820-7. 2012
    ..We investigated cetuximab with twice-weekly gemcitabine and intensity-modulated radiotherapy (IMRT) as neoadjuvant therapy in patients with localized or locally advanced PDAC...
  32. pmc Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
    M Korc
    Department of Medicine, University of California, Irvine 92717
    J Clin Invest 90:1352-60. 1992
    ....
  33. pmc Update on diabetes mellitus
    Murray Korc
    Division of Endocrinology, Department of Medicine, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Hanover, NH 03756, USA
    Dis Markers 20:161-5. 2004
    ..Proteome based technologies are providing new insights into these defects...
  34. pmc Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer
    Kazumitsu Cho
    Department of Integrative Pathology, Graduate School of Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Am J Pathol 170:1964-74. 2007
    ..KGFR and KGF may act to promote venous invasion and tumor angiogenesis in PDAC, raising the possibility that they may serve as novel therapeutic targets in anti-angiogenic strategies in PDAC...
  35. ncbi Targeted therapeutics in pancreatic cancer: a ray of hope
    Murray Korc
    Clin Cancer Res 11:410-1. 2005
  36. ncbi Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines
    Mitsuharu Fukasawa
    Department of Medicine, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 10:3327-32. 2004
    ..Although VEGF-A is overexpressed in pancreatic ductal adenocarcinoma, it is not known whether the in vivo growth of multiple pancreatic cancer cells can be efficiently blocked by VEGF-A sequestration...
  37. ncbi Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer
    Nichole Boyer Arnold
    Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Cancer Res 64:3599-606. 2004
    ..These findings suggest that TRX is downstream of Smad7 in a pathway that confers a growth advantage to pancreatic cancer cells and that increases their resistance to CDDP-mediated apoptosis, implying novel regulatory functions for Smad7...
  38. ncbi Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells
    Kimi Fukahi
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Irvine, California, USA
    Clin Cancer Res 10:581-90. 2004
    ..Neuropilin (Np)-1 and -2 are coreceptors for vascular endothelial growth factor (VEGF). This study was designed to assess their role in pancreatic ductal adenocarcinoma (PDAC)...
  39. ncbi Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis
    Michiya Yasutome
    Department of Medicine and Pharmacology, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Hanover, USA
    Clin Exp Metastasis 22:461-73. 2005
    ..However, this effect is transient, indicating that Smad4 growth inhibitory actions are circumvented in the later stages of pancreatic tumorigenicity...
  40. ncbi Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines
    Jorg Kleeff
    Division of Endocrinology, Department of Medicine, University of Heidelberg, Germany
    Pancreas 28:25-30. 2004
    ....
  41. pmc The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia
    CATHERINE CARRIERE
    Department of Medicine, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Hanover, NH 03756, USA
    Proc Natl Acad Sci U S A 104:4437-42. 2007
    ..Thus, the Nestin cell lineage is highly responsive to Kras oncogenic activation and may represent the elusive progenitor population in which PDAC arises...
  42. pmc Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells
    Takuma Aikawa
    Department of Medicine, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Hanover, New Hampshire 03756, USA
    J Clin Invest 118:89-99. 2008
    ..Thus targeting GPC1 might provide new avenues for cancer therapy and for the prevention of cancer metastasis...
  43. ncbi Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer
    Takuma Aikawa
    Department of Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Mol Cancer Ther 5:1108-16. 2006
    ..Therefore, blocking CTGF actions with FG-3019 may represent a novel therapeutic approach in pancreatic ductal adenocarcinoma...
  44. ncbi IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells
    Marko Kornmann
    Department of General Surgery, University of Ulm, Ulm, Germany
    Gastroenterology 123:301-13. 2002
    ..Pancreatic ductal adenocarcinomas (PDACs) overexpress multiple FGFs, implying a potential for growth modulation. In this study we investigated the importance of the IIIc splice variant of FGFR-1 (FGFR-1 IIIc) in PDAC...
  45. ncbi Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth
    Zhanbing Liu
    Department of General, Visceral and Transplantation Surgery, University of Ulm, Ulm, Germany
    Cancer Res 67:2712-9. 2007
    ..Our results show that FGFR1-IIIb is a functional FGFR that inhibits the transformed phenotype of human pancreatic cancer cells...
  46. ncbi The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer
    Nichole Boyer Arnold
    Department of Medicine, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Hanover, New Hampshire, USA
    Clin Cancer Res 13:18-26. 2007
    ..In this study, we sought to determine whether a relatively new histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), inhibits pancreatic cancer cell growth...
  47. ncbi Squeezing data from pancreatic juice
    Craig R Tomlinson
    Department of Medicine, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Cancer Biol Ther 5:1390-1. 2006
  48. ncbi Human fibroblast growth factor receptor 1-IIIb is a functional fibroblast growth factor receptor expressed in the pancreas and involved in proliferation and movement of pancreatic ductal cells
    Zhanbing Liu
    Department of General, Visceral and Transplantation Surgery, University of Ulm, Ulm, Germany
    Pancreas 35:147-57. 2007
    ..In this study, the expression and functionality of the human FGFR-1 IIIb were characterized in the pancreas...
  49. ncbi Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion
    Mitsuharu Fukasawa
    Department of Medicine, Pharmacology and Toxicology, and the Norris Cotton Comprehensive Cancer Center, Hanover, New Hampshire New Hampshire, USA
    Cancer Biol Ther 6:1173-80. 2007
    ..Thus, Np-1 confers a growth and survival advantage to PANC-1 cells, and interacts with integrin beta1 to coordinate signaling events that promote cell adherence and invasiveness...
  50. pmc Pancreatic cancer-associated stroma production
    Murray Korc
    Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Am J Surg 194:S84-6. 2007
    ..This unique microenvironment harbors and nourishes the cancer cells, facilitating their invasive and metastatic potential. Targeting the stroma may thus provide novel therapeutic options in this deadly malignancy...
  51. ncbi Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1
    Arikira Matsushita
    Department of Medicine, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Cancer Res 67:10309-16. 2007
    ..These findings indicate that Np-1 is required for efficient activation of c-Met-dependent pathways that promote cell invasiveness...
  52. ncbi The application of differential display as a gene profiling tool
    Ken Chien Neng Chang
    Osteoporosis Research, Women s Health Research Institute, Wyeth Research, Collegeville, PA, USA
    Methods Mol Biol 383:31-40. 2007
    ..Differential display is one of several expression profiling technologies available and is compared with some of them. The future of differential display remains bright and is as applicable today as it was in 1992...
  53. ncbi Shining the spotlight on shed KRAS in pancreatic cancer
    Lorenzo F Sempere
    Department of Medicine, Norris Cotton Cancer Center at Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Hanover, NH 03756, USA
    Cancer Biol Ther 7:361-3. 2008
  54. pmc Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues
    Anna E Szafranska
    Asuragen Inc, Austin, TX, USA
    Clin Chem 54:1716-24. 2008
    ....
  55. ncbi Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma
    Hany Kayed
    Department of General Surgery, University of Heidelberg, D 69120 Heidelberg, Germany
    Int J Oncol 29:1139-48. 2006
    ..GPC1 down-regulation suppresses pancreatic cancer cell growth and slightly modifies signaling of members of the TGF-beta family of growth factors...
  56. ncbi Expression and differential signaling of heregulins in pancreatic cancer cells
    Armin Kolb
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 120:514-23. 2007
    ..High HRG-beta levels but not HRG-alpha levels were associated with decreased patient survival. In conclusion, HRG is expressed by pancreatic cancer cells and influences pancreatic cancer cell growth and patient survival...
  57. ncbi Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor
    Kei Matsuda
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of California, Irvine, California 92697, USA
    Cancer Res 62:5611-7. 2002
    ....
  58. ncbi Induction and expression of betaig-h3 in pancreatic cancer cells
    Dominik Schneider
    Department of Visceral and Transplantation Surgery, University of Bern, Bern, Switzerland
    Biochim Biophys Acta 1588:1-6. 2002
    ....
  59. ncbi Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells
    Zhaowen Zhu
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Mol Carcinog 35:138-47. 2002
    ....
  60. ncbi Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis
    Melissa A Rowland-Goldsmith
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697, USA
    Mol Cancer Ther 1:161-7. 2002
    ..These results indicate that TGF-beta s act in vivo to enhance the expression of genes that promote the growth and metastasis of pancreatic cancer cells and suggest that sT beta RII may ultimately have a therapeutic benefit in PDAC...
  61. ncbi Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Germany
    Lab Invest 83:731-42. 2003
    ..These findings illustrate that the NK-1R pathway is activated in human pancreatic cancer and has the potential to contribute to cancer cell growth, thus suggesting the existence of a neuro-cancer cell interaction in vivo...
  62. ncbi Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells
    Quan Liao
    Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Gastroenterology 124:1830-45. 2003
    ..In view of the important role of MAPK kinase phosphatase (MKP)-1 in the regulation of MAPK activation, the expression and functional role of MKP-1 was analyzed...
  63. ncbi Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors
    Jorg Kleeff
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Irvine, California 92697, USA
    Cancer Gene Ther 9:522-32. 2002
    ....
  64. ncbi Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer
    Knut Ketterer
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of California, Irvine, California 92697, USA
    Clin Cancer Res 9:5127-36. 2003
    ..In this study we analyzed the expression and localization of NTs and their receptors in microdissected pancreatic cancer tissue samples, and studied their ability to stimulate cell growth...
  65. ncbi Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma
    Junchao Guo
    Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Oncogene 23:71-81. 2004
    ..These findings demonstrate an important role of CDC25B in cell-cycle progression, raising the possibility that inhibition of CDC25B may have therapeutic potential in pancreatic cancer...
  66. ncbi Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis
    Ahmed Guweidhi
    Department of General Surgery, University of Heidelberg, Germany
    Carcinogenesis 25:1575-85. 2004
    ....
  67. ncbi Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation
    Junsheng Li
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Int J Oncol 25:203-10. 2004
    ..Gefitinib also inhibits anchorage-independent growth and invasiveness, suggesting that gefitinib may offer a new approach for the treatment of pancreatic cancer...
  68. ncbi Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells
    Junsheng Li
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Biochem Biophys Res Commun 320:1148-55. 2004
    ..There was, however, no significant difference in TGF-beta1 induced p21 expression and Smad2 nuclear translocation. In conclusion, glypican-1 is required for efficient TGF-beta1 signaling in pancreatic cancer cells...
  69. ncbi FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth
    Hany Kayed
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 118:43-54. 2006
    ..In conclusion, overexpression of FXYD3 in pancreatic cancer may contribute to the proliferative activity of this malignancy...
  70. ncbi Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma
    Junchao Guo
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Int J Mol Med 17:761-7. 2006
    ..Together with the known function of YAP65 in different growth and differentiation regulating pathways, it is suggested that this gene plays a role in the normal and diseased pancreas...
  71. ncbi The joy of discovery
    Murray Korc
    Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Cancer Biol Ther 5:884-8. 2006
  72. ncbi Adhesion molecules in human pancreatic cancer
    Adrien A Tempia-Caliera
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    J Surg Oncol 79:93-100. 2002
    ..In the present study, we analyzed the adhesion molecules ICAM-1 (intercellular adhesion molecule-1), VCAM-1 (vascular cell adhesion molecule-1), and ELAM-1 (endothelial leukocyte adhesion molecule-1) in human pancreatic cancer...